Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus MIVACRON IN DEXTROSE 5 IN PLASTIC CONTAINER.
ARDUAN vs MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine-mediated depolarization and muscle contraction.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
Initial IV bolus of 0.15-0.2 mg/kg (following succinylcholine) or 0.25 mg/kg (without succinylcholine) over 30-60 seconds. Maintenance infusion: 8-10 mcg/kg/min for continuous neuromuscular blockade during anesthesia.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Terminal elimination half-life is approximately 2-3 minutes (0.03-0.05 h) due to rapid hydrolysis by plasma esterases; clinical duration is short, with recovery of neuromuscular function beginning within 5-10 minutes after bolus dose.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of the dose; biliary/fecal elimination accounts for the remainder, primarily as metabolites via the liver.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker